Results at 30 months of a randomised trial of FDCs and separate drugs for the treatment of tuberculosis
Study C was an open-label, non-inferiority, randomised controlled trial of fixed-dose combination (FDC) or separate drugs given during the intensive phase of treatment to 1585 patients with smear-positive pulmonary tuberculosis conducted at 11 sites in Africa, Asia and Latin America. Thirty months p...
Gespeichert in:
Veröffentlicht in: | The international journal of tuberculosis and lung disease 2014-10, Vol.18 (10), p.1252-1254 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Study C was an open-label, non-inferiority, randomised controlled trial of fixed-dose combination (FDC) or separate drugs given during the intensive phase of treatment to 1585 patients with smear-positive pulmonary tuberculosis conducted at 11 sites in Africa, Asia and Latin America.
Thirty months post-randomisation, the failure/relapse rates in the per protocol population were 7.4% of 591 patients on FDCs and 6.5% of 587 patients on separate drugs; the site-adjusted difference was 0.3% (90%CI −1.8 to 2.3). In the modified intention-to-treat analysis, the corresponding
results were respectively 17.9% of 683 and 16.1% of 671; the site-adjusted difference was 2.0% (90%CI −1.2 to 5.2). |
---|---|
ISSN: | 1027-3719 1815-7920 |
DOI: | 10.5588/ijtld.14.0281 |